Orfiril (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril, is an anticonvulsant presented as oral tablets for oral use. It is employed to control seizures, stabilize mood in bipolar disorder, and prevent migraine attacks in adult patients. GNH USA supplies Orfiril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril (sodium valproate) is used across several neurological and psychiatric conditions where modulation of neuronal excitability is required. - Epilepsy: reduces the frequency of generalized tonic‑clonic, absence and myoclonic seizures. - Bipolar disorder: stabilises mood and prevents manic or depressive episodes. - Migraine prophylaxis: decreases the number of migraine attacks per month.

Adverse reactions to sodium valproate can vary from mild to severe.

Common Side Effects: - Nausea or gastrointestinal upset. - Tremor or unsteady movements. - Weight gain or increased appetite. - Hair thinning or loss. - Drowsiness or fatigue. - Mild rash.

Serious or Rare Side Effects: - Hepatic failure or severe liver injury. - Acute pancreatitis. - Thrombocytopenia or significant drop in platelet count. - Hyperammonemic encephalopathy. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe depression or suicidal thoughts.

Before initiating therapy, clinicians should assess specific risk factors and monitor patients regularly. - Pregnancy: sodium valproate carries a high risk of neural‑tube defects; avoid unless no alternative exists. - Liver function: perform baseline and periodic hepatic enzyme tests. - Blood counts: monitor platelet and white‑cell levels for hematologic toxicity. - Renal function: adjust dosing in severe impairment. - Drug interactions: review concomitant medications for potential metabolic effects. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Sodium valproate interacts with many medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Carbamazepine: induces valproate metabolism, reducing efficacy. - Lamotrigine: combined use increases risk of severe skin reactions. - Aspirin/NSAIDs: may heighten bleeding tendency. - Warfarin: potentiates anticoagulant effect, raising INR. - Oral contraceptives: valproate reduces hormonal efficacy, risking unintended pregnancy.

Moderate Interactions (Monitor Closely): - Phenytoin: may alter plasma levels of both agents. - Phenobarbital: can increase valproate clearance. - Topiramate: may enhance central nervous system depression. - Antidepressants (SSRIs): monitor for increased sedation. - Antiepileptic polytherapy: adjust doses based on therapeutic drug monitoring.